Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) Trial
Phase 4
Completed
- Conditions
- Asthma
- Registration Number
- NCT00687310
- Lead Sponsor
- AstraZeneca
- Brief Summary
The primary purpose of this study is to assess whether tailored patient education for patients on Symbicort® Turbuhaler® therapy improves patient satisfaction, adherence and Quality of Life.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
- Patients with the diagnosis of asthma.
- Patients with asthma, where the use of Symbicort® Turbuhaler® is indicated and would have been prescribed by the investigator as part of usual care.
- Patient who have public or private insurance coverage for Symbicort® Turbuhaler® or are willing to pay for this medication for the duration of the trial.
Exclusion Criteria
- Patients who have been treated wth Symbicort® Turbuhaler® in the preceding 3 months.
- A history of smoking [i.e., 10 pack-years where one pack-year equals one pack (20 cigarettes) per day for one year, or equivalent].
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Patient's satisfaction with asthma education At the initial visit (Visit 1) and during the final call (Call 2) or at the time of premature discontinuation from the trial.
- Secondary Outcome Measures
Name Time Method Mini-asthma Quality of Life questionnaire Visit 1 and during calls 1 and 2 Asthma control parameters At baseline, as well as during Call 1 and Call 2 for both the usual care group and the enducational intervention group. PIKO meter usage assessment During the Call 2 to the educational intervention group subjects who received the PIKO meter during their educational session.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Symbicort® Turbuhaler® efficacy in asthma management?
How does tailored education compare to standard care in improving adherence to ICS-LABA therapies?
Are there specific biomarkers that predict response to inhaled corticosteroid and long-acting beta-agonist combinations in asthma patients?
What adverse events are associated with Symbicort® Turbuhaler® in phase 4 asthma trials and how are they managed?
How does Symbicort® Turbuhaler® compare to other ICS-LABA combinations like Advair or Foradil in patient-reported outcomes for asthma?